利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.04 秒)

    Metalloproteinases
    21.
    发明授权
    Metalloproteinases 失效
    金属蛋白酶

    公开(公告)号：US06312937B1

    公开(公告)日：2001-11-06

    申请号：US09372154

    申请日：1999-08-11

    申请人： Jian Ni ,  Steve Ruben ,  Laurie Brewer ,  Reiner Gentz ,  Craig Rosen

    发明人： Jian Ni ,  Steve Ruben ,  Laurie Brewer ,  Reiner Gentz ,  Craig Rosen

    IPC分类号： C12N950

    CPC分类号： C12N9/6489 ,  A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70535 ,  C12N9/00 ,  C12N9/6475 ,  C12N9/6491 ,  C12N2799/026

    摘要： The present invention relates to novel metalloproteinase- like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.

    摘要翻译： 本发明涉及新型金属蛋白酶样蛋白质。 特别地，提供了分离的核酸分子，其编码人类TACE样和基质溶素样蛋白。 TACE样和基质溶素样多肽也可以作为载体，宿主细胞和用于制备它们的重组方法提供。 本发明进一步涉及用于鉴定TACE样和基质溶素样活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测癌症的诊断方法和癌症的治疗方法以及特征在于这些金属蛋白酶过度或过量生产的其它病症。

    Metalloproteinases
    22.
    发明授权
    Metalloproteinases 失效
    金属蛋白酶

    公开(公告)号：US6046031A

    公开(公告)日：2000-04-04

    申请号：US9156

    申请日：1998-01-20

    申请人： Jian Ni ,  Steve Ruben ,  Laurie Brewer ,  Reiner Gentz ,  Craig Rosen

    发明人： Jian Ni ,  Steve Ruben ,  Laurie Brewer ,  Reiner Gentz ,  Craig Rosen

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/735 ,  C12N1/21 ,  C12N9/00 ,  C12N9/64 ,  C12N15/57 ,  C12P21/06

    CPC分类号： C12N9/6489 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70535 ,  C12N9/00 ,  C12N9/6475 ,  C12N9/6491 ,  A61K38/00 ,  C12N2799/026

    摘要： The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.

    摘要翻译： 本发明涉及新型金属蛋白酶样蛋白质。 特别地，提供了分离的核酸分子，其编码人类TACE样和基质溶素样蛋白。 TACE样和基质溶素样多肽也可以作为载体，宿主细胞和用于制备它们的重组方法提供。 本发明进一步涉及用于鉴定TACE样和基质溶素样活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测癌症的诊断方法和癌症的治疗方法以及特征在于这些金属蛋白酶过度或过量生产的其它病症。

    Lung cancer markers, and uses thereof
    23.
    发明授权
    Lung cancer markers, and uses thereof 有权
    肺癌标志物及其用途

    公开(公告)号：US08808997B2

    公开(公告)日：2014-08-19

    申请号：US13005031

    申请日：2011-01-12

    申请人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

    发明人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

    IPC分类号： G01N33/53

    CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

    摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

    摘要翻译： 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。

    Lung cancer markers, and uses thereof
    26.
    发明授权
    Lung cancer markers, and uses thereof 有权
    肺癌标志物及其用途

    公开(公告)号：US07892760B2

    公开(公告)日：2011-02-22

    申请号：US12273994

    申请日：2008-11-19

    申请人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

    发明人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

    IPC分类号： G01N33/53

    CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

    摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

    摘要翻译： 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂）及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。